SSA
AXDX

Schonfeld Strategic Advisors’s Accelerate Diagnostics AXDX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,850
Closed -$583K – 1360
2020
Q2 		$583K Buy
+3,850
New +$380K 0.02% 754

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Schonfeld Strategic Advisors's AXDX Position: Q3 2020 in Review

Schonfeld Strategic Advisors sold out of Accelerate Diagnostics (AXDX) in Q3 2020, closing a stake of 3,850 shares — an estimated $583K sold.

Schonfeld Strategic Advisors first reported a position in AXDX in Q2 2020 and held it in 1 quarter. The position peaked at $583K in Q2 2020. 112 funds tracked by Wall St. Rank hold AXDX as of Q3 2020.

  • Schonfeld Strategic Advisors reported no remaining Accelerate Diagnostics position as of Q3 2020 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 3,850 Accelerate Diagnostics shares in Q3 2020, an estimated $583K.
  • Schonfeld Strategic Advisors first reported a position in Accelerate Diagnostics in Q2 2020 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Accelerate Diagnostics position peaked at $583K in Q2 2020.
  • 112 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2020.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.